Shares of Kodiak Sciences Inc. KOD faced a sharp decline during Thursday’s trading session
following a wider-than-expected fourth-quarter loss declaration.

Kodiak Sciences registered a quarterly loss of $1.13 per share,
significantly deviating from the market’s projection of a 77 cents per share deficit.

The stock of Kodiak Sciences witnessed a substantial 19.9% decrease,
trading at $5.97 by the day’s end.

Diving deeper into the market movements for the day, a number of other
stocks experienced noteworthy shifts.

Winners

• Avalo Therapeutics, Inc. AVTX shares surged by a
  staggering 430%, reaching $25.35 post-announcement of the acquisition of a Phase 2-ready
  anti-IL-1β mAb known as AVTX-009 and a private placement financing of up to $185 million through
  the acquisition of AlmataBio.
• Xilio Therapeutics, Inc. XLO experienced a notable
  gain of 146% to $1.58 following its exclusive license agreement with Gilead Sciences for a
  tumor-activated IL-12 program and a $11.3 million private placement equity financing.
• Biodexa Pharmaceuticals Plc BDRX observed an 80% jump to
  $1.5395 as MTX110 showcased promising results in extending life expectancy against aggressive
  brain cancers.
• Ontrak, Inc. OTRK witnessed a 55% increase to $0.9239.
• Binah Capital Group, Inc. BCG rebounded with a 48% rise to
  $14.05 after a notable 20% decline the prior day.
• Kidpik Corp. PIK soared by 40.7% to $4.5999 as the company regained
  compliance with the Nasdaq minimum bid price requirement.
• Allego N.V. ALLG rose by 32.8% to $1.7650.
• Akanda Corp. AKAN surged by 28% to $0.2053 after outlining plans to
  explore opportunities in Bitcoin, Blockchain, and AI applications within the cannabis sector.
• Destiny Tech100 Inc. DXYZ experienced a 26% surge to
  $22.15.
• REX American Resources Corporation REX climbed by 23.2% to $54.15
  post-encouraging earnings announcements.
• Nutriband Inc. NTRB rose by 23% to $4.98 after providing an overview
  of the clinical and regulatory pathway for its AVERSA Fentanyl patch.
• Summit Therapeutics Inc. SMMT gained 22.8% to $4.6050.
• CERo Therapeutics Holdings, Inc. CERO observed a 22.7% increase
  to $2.00.
• Hut 8 Corp. HUT noted a 20.4% gain, trading at $11.87 after
  reporting revenue of C$60.6 million for the six months ending Dec. 31, 2023.
• Matterport, Inc. MTTR rose by 16.8% to $2.2802.
• RH RH experienced a 16.2% increase to $344.99 post-quarterly
  results declaration. While RH reported weaker-than-expected fourth-quarter results, it issued an
  optimistic forecast.
• Cazoo Group Ltd CZOO surged by 15.5% to $14.52 following a triple-digit
  increase the previous day.
• Sutro Biopharma, Inc. STRO rose by 14.4% to $5.64.
  Analyst Jay Olson from Oppenheimer maintained an Outperform rating for Sutro Biopharma with a
  price target of $10.
• Kintara Therapeutics, Inc. KTRA shares rose by 14.1% to
  $0.1021 following the announcement of the expansion of the REM-001 clinical study to include
  patients on pembrolizumab.
• Nikola Corporation NKLA saw a rise of 12.7% to
  $1.0250.
• OPKO Health, Inc. OPK climbed by 12.1% to $1.1996.
  Labcorp announced the acquisition of select assets of BioReference Health’s Diagnostics Business.
• Altimmune, Inc. ALT noted an 11.4% increase to
  $9.90. Altimmune released lean mass preservation data for pemvidutide along with worse-than-expected
  fourth-quarter FY23 earnings.
• Marathon Digital Holdings, Inc. MARA gained 10.4% to $24.37.
• Ginkgo Bioworks Holdings, Inc. DNA rose by 7.1% to $1.1786. The company
  announced a contract award of up to $6 million from the Defense Advanced Research Projects Agency.
• The Estée Lauder Companies Inc. EL saw a 5.4% increase to $152.85
  after an upgrade from Neutral to Buy by B of A Securities, along with a raised price target from
  $160 to $170.

Losers

• Primech Holdings Ltd. PMEC witnessed a 46.7% decline to
  $2.07 following the company’s financial updates and corporate highlights release for the six
  months ended Sept. 30.